Pfizer exits neuroscience
Nature Reviews Drug Discovery 17, 86 (2018).
doi:10.1038/nrd.2018.16
Author: Asher Mullard
Pfizer is pulling out of neuroscience drug discovery and early development, and cutting 300 positions in its neuroscience division.Prior to the announcement, the company had eight neuroscience products in phase I and phase II trials. These consisted of four clinical programmes in Alzheimer disease,
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research